ASPN Chairman Tim Deer, MD, discusses the research and innovation at ASPN 2024 and the society’s collaborative approach to improving care for patients with chronic intractable pain in an interview with SmartTRAK.

Timothy R. Deer, MD, chairman of the American Society of Pain and Neuroscience (ASPN), discusses the society's goals, its rapid growth, and how ASPN is collaborating with different stakeholders to improve patient care and offer a wider range of new and innovative treatment options for patients with chronic intractable pain. To find out more, including what’s new in neuromodulation, minimally invasive spine and regenerative medicine, listen to the following video recorded live at the ASPN 2024 Annual Conference held July 11-14, 2024 in Miami Beach, FL. A link to download the complete transcript of the interview is also provided below. 

SmartTRAK: Anne Staylor here with SmartTRAK. I'm at the beautiful Fontainebleau Hotel in balmy Miami Beach, Florida at the American Society of Pain and Neuroscience Annual Conference. Today is the last day of the conference and I have the pleasure of talking with Dr. Tim Deer, the chairman of ASPN. Dr. Deer, thank you for talking with me today.

Dr. Tim Deer: Anne, thank you so much for having me. It's a great pleasure to talk to you and thank you for coming to our meeting.

Yes. Well, as you know, I think three years ago was the last time I was at your meeting, and I've had a colleague cover it who lives on the East Coast since then. Now I'm back covering the meeting and wow, has it grown exponentially since you and Dr. Sayed co-founded this meeting. I think this year, there's been a lot of energy and vibrancy around the content and in the exhibit hall and honestly, there's so much news for me to cover.

But before we get into the meeting, I thought it'd be a good idea to have you start by talking about the meeting itself, how it's grown, what the attendance has been this year, et cetera. And then what have been some of the key goals of society? And what have you and your vice chair, Dr. Sayed, been working toward as a society since you established the meeting?

SmartTRAK experts across orthopedics, sports medicine, spine and enabling technology attended this year’s 2024 Canaccord Genuity Musculoskeletal and American Academy of Orthopedic Surgeons (AAOS) annual conferences. Held from February 12-15 in San Francisco, CA, these gatherings brought together the top minds in the industry. In this post, we share some key insights and updates gleaned from these conferences, offering a glimpse into the latest trends and innovations shaping the future of orthopedic and musculoskeletal care.

• MARKET

Maxx Orthopedics*
SmartTRAK learned at AAOS 2024 that Maxx Medical is going on the offensive to grow its joint replacement business in the US and that the Company plans to launch new hip and knee products in 2024.

Paragon 28*
At AAOS 2024, Paragon 28 noted that its supply chain issues have resolved and does not expect a headwind this year. As a result, Needham believes the company can return to ~20% revenue growth in 2024.

restor3d*
Restor3d reported it currently has 157 active distribution partners calling on ~22,965 orthopedic surgeons and ~18,000 podiatrists. Management noted surgeons will bring difficult cases and from there restor3d can create additional sales opportunities. CG 2024 Musculoskeletal Conference

• REVENUES

BONESUPPORT*
BONESUPPORT highlighted the continued strength of Cerament G in North America with approximate revenues of $17.0MM in Q323 since launching in June 2023. CG 2024 Musculoskeletal Conference

OrthAlign*
At AAOS 2024, SmartTRAK learned that OrthAlign’s 2023 revenue was up +25% to $51MM, led by strong adoption of its Lantern next-generation handheld navigation system and increasing use of the Balance gap balancing feature on Lantern Knee. The company noted +37% growth in the ASC setting.

Throughout 2023, SmartTRAK led the way in helping you Be The Expert in the MedTech industry. Serving as your trusted resource for the latest industry developments, we provided real-time market data and analysis across the orthopedic, wound care, regenerative medicine and neurotherapy sectors.  Presenting SmartTRAK's Top 12 Blog Posts from 2023, featuring indispensable insights from our expert analysts.

1. Could Reverse Hips Change the Total Hip Game?
   Hip Innovation Technology is betting on its Reverse HRS Hip to change the practice of total hip replacement
   
   
2. Three Ortho Robotics Companies to Watch in 2023
   SmartTRAK identifies three orthopedic robotics companies strategically positioned to shake things up this year in the fast-growing robotic-assisted TJA market.
   
   
3. Saluda Medical: Changing the Game in Spinal Cord Stimulation
   Saluda Medical President and CEO Jim Schuermann discusses the Company, the Evoke System and changing the game in SCS in an interview with SmartTRAK.
   
   
   
   

New SaaS technology offering delivers competitive advantage in rapidly changing Ambulatory Surgery Center market.

SmartTRAK, the leading global Medtech business and market software intelligence solution in the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets, announces the release of enhanced software products and strategic reports available for purchase in Q4 to help clients position themselves for growth in 2024 and beyond.

The interest and demand for regenerative medicine for various conditions and injuries have increased exponentially over the last decade. From January 1, 1990 to December 31, 2012, google searches for regenerative medicine totaled 21,600,000. With increased publicity about stem cells and advancements in cell and gene therapies, biomaterials and tissue engineering, google searches increased nearly ten-fold to 212,000,000 from 1/1/13 to 2/27/23.

• PRP Trends and the Impacts to 2023 and Beyond
  
  • Headwinds in 2023
  • Trends in PRP Clinical Trials
  • Anticipated 2023 US PRP Market Share Standings
• Adipose Trends and the Impacts to 2023 and Beyond
  • Adipose tissue therapy gaining interest in the field of sports medicine
  • Patient demand for minimally-invasive solutions
  • Adipose-derived cell therapies for OA and Degenerative Disc Disease
    

So is regenerative medicine the way of the future? Time will tell, however, SmartTRAK feels that demand and interest by multiple stakeholders, along with recent trends, medical and legal advancements and investments is tipping the scale to ...

To download and read the complete "A Glimpse into 2023: Regen Med Trends" article by Freddy Buntoum, SmartTRAK's Senior Analyst, Orthobiologics and Regenerative Medicine, just click the button below.

Do you love keeping up with the latest trends in the Spine and OrthoBiologics/Regen medicine markets? Are you a closet investigative reporter who loves researching and analyzing what’s going on in the market? Are you looking for a position that leverages your industry knowledge, expertise and connections in new ways? If you are a current or former marketing, market research or business development professional who has worked with one of the major orthopedic/spine companies and looking for a career change, we would love to talk with you.

We are looking to strengthen our SmartTRAK Spine and OrthoBiologics/Regen modules with the addition of a qualified person with industry specific experience. All SmartTRAK analysts are former marketing, business development or R&D professionals with one of the major orthopedic/spine suppliers and, in fact, most have come to us via recommendations from our subscribers, as well as those in the industry. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add we can offer SmartTRAK subscribers.

We are looking for someone with Spine and OrthoBiologics/Regen industry experience who is interested in working full-time. Click the button below to learn more and apply.

Highlighting the latest research, technology developments and innovations taking place in orthobiologics and regenerative medicine at ICRS 2022

This year the International Cartilage Regenerative & Joint Preservation Society (ICRS) hosted its 16th World Congress in Berlin, Germany, and SmartTRAK covered it. This was the Society’s first in-person meeting since October 2019, and without a doubt, a very exciting moment for ICRS, its members and all who attended the event. For four days, industry stakeholders from around the world converged in Berlin to learn and hear about the latest research, technology developments and innovations taking place in orthobiologics and regenerative medicine. In this article, SmartTRAK gives a recap of some of the main topics presented during the meeting.

Among the many fascinating topics covered in the complete article, which can be downloaded here, are:

• The Role of Extracellular Vesicles 
• Use of Minced Cartilage
• Autologous, Matrix-induced Chondrogenesis 
• Feasibility of Gene Therapy
• Other Therapies of Tomorrow

Observations and analysis from the 37th Annual North American Spine Society (NASS) Meeting held October 12-14 in Chicago, IL. 

SmartTRAK highlights the top news and themes at NASS 2022 affecting the markets for OrthoBio and Regenerative Medicine, including the Orthofix/SeaSpine  merger, the ongoing controversy surrounding BMP-2, new product launches, company growth strategies and the latest research and innovation in intradiscal therapies.

Among the many topics covered in detail in this article are:

• A Spine Merger That Will Significantly Impact The Orthobiologics Landscape
• BMP-2 Safety Profile Remains an Open Issue
• Incremental Product Improvement Across OrthoBio Categories
• Spine Strategic Portfolio Strategies
• Intradiscal Treatments Take Center Stage

Undoubtedly, the proposed business combination of Orthofix and SeaSpine announced immediately prior to NASS was the most impactful news emanating from the meeting. On a proforma basis, the combined company is expected to generate approximately ...

To download and read the complete "OrthoBio-Focused Themes Emerging from NASS 2022" article by James Petricek,  SmartTRAK's GM, OrthoBio and Regenerative Medicine, just click the button below.

Mr J. David Owens, President & CEO of BiologicsMD, and Chief Scientific Officer, Dr. Robyn Goforth, discuss the Company’s highly-targeted therapies, a series of recombinant fusion proteins designed to treat hair loss and severe bone disorders, in an interview with SmartTRAK.

In an interview with SmartTRAK, BiologicsMD President & CEO J. David Owens and CSO Dr. Robyn Goforth discuss BiologicsMD’s innovative highly-targeted treatments for severe bone disorders and hair loss diseases.

To find out more about this early-stage company, the science behind highly-targeted therapies, and two of its lead compounds, click on the following video to listen to the full interview (29:10 min). A link to download a complete transcript of the interview is also provided below.

From the impact of stringent regulations to the shift toward new indications and rising market segments, SmartTRAK explores some of the trends to watch for in 2022 and beyond.

Orthopedic regenerative medicine therapy as an emerging area of science holds great promise for treating and promoting faster healing in a variety of injuries. There is also a belief among some scientists and industry stakeholders that it may hold the key to halting or reversing degenerative chronic conditions through self-healing. In a previous article, SmartTRAK had highlighted several challenges that Regenerative Medicine therapies would need to overcome to become a fully viable business and recognized treatment solution for patients. In 2021, businesses, societies and health care systems across the world continued to experience disruptions from the COVID-19 pandemic and its subsequent waves of variants. Furthermore, much greater scrutiny and tougher regulations for some of the injectable regenerative medicine therapies were put into place. The start of 2022 is also not quite as “rosy” as most had hoped for ...